secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001213900-26-016912
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne Q1 net loss $1.4M; guides FY26 product revenue at least $10.5M
-----------------------------------------------------------------------

- Q1 product revenue $2.9M (down 12% YoY, but up 5.5% sequentially from Q4 FY25).
- Net loss $1.4M ($0.03/sh) vs net income $1.8M ($0.06/sh) in Q1 FY25 due to no license revenue.
- Cash $3.6M as of Dec 31, 2025; funded through FY26 if milestones hit.
- Completed 9 trigeminal neuralgia cases after FDA clearance; all patients reportedly pain free.
- Expects FY26 product revenue of at least $10.5M, a 17% YoY increase from $9.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026016912/0001213900-26-016912-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390026016912/ea0277131-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-016912

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer